These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35745144)

  • 1. Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Racaniello D; Fanelli M; Colaianni V; Vozza A; Triggiani V; Sabbà C; Tortorella C; De Pergola G; Piazzolla G
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Lavarra V; Triggiani D; Crudele L; Triggiani V; Sabbà C; De Pergola G; Piazzolla G
    Front Endocrinol (Lausanne); 2023; 14():1240263. PubMed ID: 37780624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Triggiani D; Donghia R; Crudele L; Rinaldi R; Sabbà C; Triggiani V; De Pergola G; Piazzolla G
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.
    Pantanetti P; Cangelosi G; Alberti S; Di Marco S; Michetti G; Cerasoli G; Di Giacinti M; Coacci S; Francucci N; Petrelli F; Ambrosio G; Grinta R
    Front Endocrinol (Lausanne); 2024; 15():1394506. PubMed ID: 39015186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.
    Rodríguez Jiménez B; Rodríguez de Vera Gómez P; Belmonte Lomas S; Mesa Díaz ÁM; Caballero Mateos I; Galán I; Morales Portillo C; Martínez-Brocca MA
    Front Endocrinol (Lausanne); 2024; 15():1386542. PubMed ID: 38894744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
    McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
    Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
    Mohammedi K; Belhatem N; Berentzen TL; Catarig AM; Potier L
    Diabetes Obes Metab; 2023 Jul; 25(7):1855-1864. PubMed ID: 36869853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
    Rudofsky G; Catarig AM; Favre L; Grau K; Häfliger S; Thomann R; Schultes B
    Diabetes Res Clin Pract; 2021 Aug; 178():108931. PubMed ID: 34217773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
    Rajamand Ekberg N; Bodholdt U; Catarig AM; Catrina SB; Grau K; Holmberg CN; Klanger B; Knudsen ST
    Prim Care Diabetes; 2021 Oct; 15(5):871-878. PubMed ID: 34183269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
    Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J
    Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
    Aroda VR; Blonde L; Pratley RE
    Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.